Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Non-cash Items (2023 - 2024)

IceCure Medical has reported Non-cash Items over the past 3 years, most recently at $3.0 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 2947.02% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 2947.02%, while the annual FY2025 figure was $3.0 million, 28.63% up from the prior year.
  • Non-cash Items was $3.0 million for Q4 2025 at IceCure Medical, up from $100000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $3.0 million in Q4 2025 and bottomed at $100000.0 in Q4 2024.
  • The 3-year median for Non-cash Items is $1.6 million (2023), against an average of $1.6 million.
  • Year-over-year, Non-cash Items plummeted 93.71% in 2024 and then soared 2947.02% in 2025.
  • Over 3 years, Non-cash Items stood at $1.6 million in 2023, then plummeted by 93.71% to $100000.0 in 2024, then soared by 2947.02% to $3.0 million in 2025.
  • The last three reported values for Non-cash Items were $3.0 million (Q4 2025), $100000.0 (Q4 2024), and $1.6 million (Q4 2023) per Business Quant data.